论文部分内容阅读
目的观察多西紫杉醇联合奥沙利铂治疗晚期上皮性卵巢癌的临床疗效及不良反应。方法将2010年6月至2014年4月60例晚期上皮性卵巢癌患者随机分为观察组和对照组各30例。观察组以多西紫杉醇75 mg/m2,持续静脉滴注,第1天;奥沙利铂130 mg/m2,持续静脉滴注,第2天;28 d为1个周期。对照组以紫杉醇135 mg/m2,持续静脉滴注,第1天;卡铂[曲线下面积(AUC)=5.0],持续静脉滴注,第1天;28 d为1个周期。两组患者均化疗2个周期后进行评价,同时详细记录化疗过程中出现的毒副作用。结果观察组近期总有效率为70.0%,对照组为66.7%,两组比较差异无统计学意义(P>0.05)。60例患者肿瘤标志物糖类抗原125(CA125)治疗后较治疗前均明显降低(P均<0.05)。两组不良反应发生率(除周围神经毒性外)比较均无统计学差异(P>0.05),均无肝肾损害、心肌损害等异常发生,无治疗相关性死亡。结论多西紫杉醇联合奥沙利铂治疗晚期上皮性卵巢癌具有较好的近期疗效,且毒副作用小,患者耐受性佳。
Objective To observe the clinical efficacy and adverse reactions of docetaxel and oxaliplatin in the treatment of advanced epithelial ovarian cancer. Methods Sixty patients with advanced epithelial ovarian cancer from June 2010 to April 2014 were randomly divided into observation group and control group with 30 cases each. Patients in the observation group were given docetaxel 75 mg / m 2 intravenously on the first day, oxaliplatin 130 mg / m 2 on the second day and 28 days for one cycle. The control group was given intravenous infusion of paclitaxel 135 mg / m2 on the first day, carboplatin [area under the curve (AUC) = 5.0] for continuous intravenous drip on day 1 and 28 days for 1 cycle. Two groups of patients were evaluated after two cycles of chemotherapy, while recording the side effects of chemotherapy in detail. Results The total effective rate was 70.0% in the observation group and 66.7% in the control group. There was no significant difference between the two groups (P> 0.05). The tumor marker carbohydrate antigen 125 (CA125) in 60 patients was significantly lower than that before treatment (all P <0.05). There was no significant difference between the two groups (except for peripheral neurotoxicity) (P> 0.05), no abnormalities such as liver and kidney damage, myocardial damage, and no treatment-related death. Conclusion Docetaxel combined with oxaliplatin in the treatment of advanced epithelial ovarian cancer has better short-term curative effect, less side effects and better patient tolerance.